• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

GlucoModicum unveils Sofio needle-free CGM

December 18, 2025 By Sean Whooley

GlucoModicum Sofio needle-free glucose monitor (1)
The Sofio needle-free glucose monitor. [Image courtesy of GlucoModicum]
GlucoModicum today unveiled Sofio, which it labels the world’s first needle-free glucose monitor based on magneto-hydrodynamics (MHD).

MHD technology draws micro-samples of interstitial fluid through the skin. It measures glucose with established electrochemical sensor technology. The single-day sensor system delivers a periodic, personalized monitoring alternative to standard continuous glucose monitor (CGM) devices.

Helsinki, Finland-based GlucoModicum’s method, like existing CGMs from Abbott and Dexcom, measures glucose through established glucose oxidase enzyme chemistry. However, the company aims to offer an option for people who don’t require 24/7 monitoring.

GlucoModicum said it developed Sofio with the idea in mind that type 2 diabetes “is not static.” With glucose patterns shifting alongside lifestyle, medication, genetics and age, the company said it wanted to provide an option for people with type 2 diabetes who don’t need a sensor attached to them for weeks at a time.

Sofio enables single-day glucose monitoring sessions with deeper insights when needed. That includes during dietary or lifestyle changes, medication adjustments or periodic checkups.

The system features a durable, rechargeable transmitter that lasts up to two years. It has a gentle, replaceable single-day sensor for those looking to avoid continuous wear.

Clinical study data previously demonstrated accuracy in line with regulatory expectations for interstitial glucose monitoring. Earlier this year, the company reported a mean absolute relative difference (MARD, a measure of CGM accuracy) of 11.5%. This approaches the industry benchmark of 10% set by needle-based CGM, the company says.

GlucoModicum said it engineered Sofio for mass manufacturability and established production partnerships for the device. It plans to progress through European regulatory pathways soon, with further updates — including related to its U.S. and FDA strategy — set to come in 2026.

“Needle-free glucose monitoring has been one of the most elusive goals in diabetes management for over thirty years,” said Jokke Mäki, CEO of GlucoModicum. “Our MHD-based approach takes a different route, enabling accurate glucose measurement without needles while relying on the established biosensing chemistry used in clinical devices.”

Visit here to purchase our Medtech Market Special Report on CGMs.

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: GlucoModicum

IN CASE YOU MISSED IT

  • Tandem’s Mobi pump wins FDA clearance for 7-day tubeless wearable set
  • Senseonics delivers ‘breakout quarter’ more than doubling Eversense 365 revenue
  • Tandem Diabetes Care names successor as CEO Sheridan retires
  • MiniMed names new CMO ahead of planned retirement
  • Insulet earnings trounce Q3 estimates as it narrows guidance

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS